TY  - JOUR
AU  - Malfertheiner, Peter
AU  - Megraud, Francis
AU  - Rokkas, Theodore
AU  - Gisbert, Javier P.
AU  - Liou, Jyh-Ming
AU  - Schulz, Christian
AU  - Gasbarrini, Antonio
AU  - Hunt, Richard H.
AU  - Leja, Marcis
AU  - O’Morain, Colm
AU  - Rugge, Massimo
AU  - Suerbaum, Sebastian
AU  - Tilg, Herbert
AU  - Sugano, Kentaro
AU  - El-Omar, Emad M.
AU  - Agreus, L.
AU  - Bazzoli, F
AU  - Bordin, D
AU  - Loginov, A.S.
AU  - Mario, F. D.
AU  - Dinis-Ribeiro, M.
AU  - Engstrand, Lars
AU  - Fallone, C
AU  - Goh, K.L.
AU  - Graham, David
AU  - Kuipers, E.J.
AU  - Kupcinskas, J.
AU  - Lanas, A.
AU  - Machado, Jose C.
AU  - Mahachai, V.
AU  - Marshall, B.J.
AU  - Milosavljevic, Tomica
AU  - Moss, S.F.
AU  - Park, J.Y.
AU  - Niv, Y.
AU  - Rajilić-Stojanović, Mirjana
AU  - Ristimaki, A
AU  - Smith, S.
AU  - Tepeš, Bojan
AU  - Wu, C.Y.
AU  - Zhou, L.
PY  - 2022
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/6050
AB  - elicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/ Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.
PB  - BMJ Publishing Group
T2  - Guidelines
T1  - Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
EP  - 1762
IS  - 9
SP  - 1724
VL  - 71
DO  - 10.1136/gutjnl-2022-327745
ER  - 

@article{
author = "Malfertheiner, Peter and Megraud, Francis and Rokkas, Theodore and Gisbert, Javier P. and Liou, Jyh-Ming and Schulz, Christian and Gasbarrini, Antonio and Hunt, Richard H. and Leja, Marcis and O’Morain, Colm and Rugge, Massimo and Suerbaum, Sebastian and Tilg, Herbert and Sugano, Kentaro and El-Omar, Emad M. and Agreus, L. and Bazzoli, F and Bordin, D and Loginov, A.S. and Mario, F. D. and Dinis-Ribeiro, M. and Engstrand, Lars and Fallone, C and Goh, K.L. and Graham, David and Kuipers, E.J. and Kupcinskas, J. and Lanas, A. and Machado, Jose C. and Mahachai, V. and Marshall, B.J. and Milosavljevic, Tomica and Moss, S.F. and Park, J.Y. and Niv, Y. and Rajilić-Stojanović, Mirjana and Ristimaki, A and Smith, S. and Tepeš, Bojan and Wu, C.Y. and Zhou, L.",
year = "2022",
abstract = "elicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/ Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.",
publisher = "BMJ Publishing Group",
journal = "Guidelines",
title = "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report",
pages = "1762-1724",
number = "9",
volume = "71",
doi = "10.1136/gutjnl-2022-327745"
}

Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O’Morain, C., Rugge, M., Suerbaum, S., Tilg, H., Sugano, K., El-Omar, E. M., Agreus, L., Bazzoli, F., Bordin, D., Loginov, A.S., Mario, F. D., Dinis-Ribeiro, M., Engstrand, L., Fallone, C., Goh, K.L., Graham, D., Kuipers, E.J., Kupcinskas, J., Lanas, A., Machado, J. C., Mahachai, V., Marshall, B.J., Milosavljevic, T., Moss, S.F., Park, J.Y., Niv, Y., Rajilić-Stojanović, M., Ristimaki, A., Smith, S., Tepeš, B., Wu, C.Y.,& Zhou, L.. (2022). Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. in Guidelines
BMJ Publishing Group., 71(9), 1724-1762.
https://doi.org/10.1136/gutjnl-2022-327745

Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J, Schulz C, Gasbarrini A, Hunt RH, Leja M, O’Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM, Agreus L, Bazzoli F, Bordin D, Loginov A, Mario FD, Dinis-Ribeiro M, Engstrand L, Fallone C, Goh K, Graham D, Kuipers E, Kupcinskas J, Lanas A, Machado JC, Mahachai V, Marshall B, Milosavljevic T, Moss S, Park J, Niv Y, Rajilić-Stojanović M, Ristimaki A, Smith S, Tepeš B, Wu C, Zhou L. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. in Guidelines. 2022;71(9):1724-1762.
doi:10.1136/gutjnl-2022-327745 .

Malfertheiner, Peter, Megraud, Francis, Rokkas, Theodore, Gisbert, Javier P., Liou, Jyh-Ming, Schulz, Christian, Gasbarrini, Antonio, Hunt, Richard H., Leja, Marcis, O’Morain, Colm, Rugge, Massimo, Suerbaum, Sebastian, Tilg, Herbert, Sugano, Kentaro, El-Omar, Emad M., Agreus, L., Bazzoli, F, Bordin, D, Loginov, A.S., Mario, F. D., Dinis-Ribeiro, M., Engstrand, Lars, Fallone, C, Goh, K.L., Graham, David, Kuipers, E.J., Kupcinskas, J., Lanas, A., Machado, Jose C., Mahachai, V., Marshall, B.J., Milosavljevic, Tomica, Moss, S.F., Park, J.Y., Niv, Y., Rajilić-Stojanović, Mirjana, Ristimaki, A, Smith, S., Tepeš, Bojan, Wu, C.Y., Zhou, L., "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report" in Guidelines, 71, no. 9 (2022):1724-1762,
https://doi.org/10.1136/gutjnl-2022-327745 . .

TY  - JOUR
AU  - Rajilić-Stojanović, Mirjana
AU  - Figueiredo, Ceu
AU  - Smet, Annemieke
AU  - Hansen, Richard
AU  - Kupcinskas, Juozas
AU  - Rokkas, Theo
AU  - Andersen, Leif
AU  - Machado, Jose C.
AU  - Ianiro, Gianluca
AU  - Gasbarrini, Antonio
AU  - Leja, Marcis
AU  - Gisbert, Javier P.
AU  - Hold, Georgina L.
PY  - 2020
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/4478
AB  - Background Helicobacter pylori is the most infamous constituent of the gastric microbiota and its presence is the strongest risk factor for gastric cancer and other gastroduodenal diseases. Although historically the healthy stomach was considered a sterile organ, we now know it is colonised with a complex microbiota. However, its role in health and disease is not well understood. Aim To systematically explore the literature on the gastric microbiota in health and disease as well as the gut microbiota after bariatric surgery. Methods A systematic search of online bibliographic databases MEDLINE/EMBASE was performed between 1966 and February 2019 with screening in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Randomised controlled trials, cohort studies and observational studies were included if they reported next-generation sequencing derived microbiota analysis on gastric aspirate/tissue or stool samples (bariatric surgical outcomes). Results Sixty-five papers were eligible for inclusion. With the exception of H pylori-induced conditions, overarching gastric microbiota signatures of health or disease could not be determined. Gastric carcinogenesis induces a progressively altered microbiota with an enrichment of oral and intestinal taxa as well as significant changes in host gastric mucin expression. Proton pump inhibitors usage increases gastric microbiota richness. Bariatric surgery is associated with an increase in potentially pathogenic proteobacterial species in patient stool samples. Conclusion While H pylori remains the single most important risk factor for gastric disease, its capacity to shape the collective gastric microbiota remains to be fully elucidated. Further studies are needed to explore the intricate host/microbial and microbial/microbial interplay.
PB  - Wiley, Hoboken
T2  - Alimentary Pharmacology & Therapeutics
T1  - Systematic review: gastric microbiota in health and disease
EP  - 602
IS  - 6
SP  - 582
VL  - 51
DO  - 10.1111/apt.15650
ER  - 

@article{
author = "Rajilić-Stojanović, Mirjana and Figueiredo, Ceu and Smet, Annemieke and Hansen, Richard and Kupcinskas, Juozas and Rokkas, Theo and Andersen, Leif and Machado, Jose C. and Ianiro, Gianluca and Gasbarrini, Antonio and Leja, Marcis and Gisbert, Javier P. and Hold, Georgina L.",
year = "2020",
abstract = "Background Helicobacter pylori is the most infamous constituent of the gastric microbiota and its presence is the strongest risk factor for gastric cancer and other gastroduodenal diseases. Although historically the healthy stomach was considered a sterile organ, we now know it is colonised with a complex microbiota. However, its role in health and disease is not well understood. Aim To systematically explore the literature on the gastric microbiota in health and disease as well as the gut microbiota after bariatric surgery. Methods A systematic search of online bibliographic databases MEDLINE/EMBASE was performed between 1966 and February 2019 with screening in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Randomised controlled trials, cohort studies and observational studies were included if they reported next-generation sequencing derived microbiota analysis on gastric aspirate/tissue or stool samples (bariatric surgical outcomes). Results Sixty-five papers were eligible for inclusion. With the exception of H pylori-induced conditions, overarching gastric microbiota signatures of health or disease could not be determined. Gastric carcinogenesis induces a progressively altered microbiota with an enrichment of oral and intestinal taxa as well as significant changes in host gastric mucin expression. Proton pump inhibitors usage increases gastric microbiota richness. Bariatric surgery is associated with an increase in potentially pathogenic proteobacterial species in patient stool samples. Conclusion While H pylori remains the single most important risk factor for gastric disease, its capacity to shape the collective gastric microbiota remains to be fully elucidated. Further studies are needed to explore the intricate host/microbial and microbial/microbial interplay.",
publisher = "Wiley, Hoboken",
journal = "Alimentary Pharmacology & Therapeutics",
title = "Systematic review: gastric microbiota in health and disease",
pages = "602-582",
number = "6",
volume = "51",
doi = "10.1111/apt.15650"
}

Rajilić-Stojanović, M., Figueiredo, C., Smet, A., Hansen, R., Kupcinskas, J., Rokkas, T., Andersen, L., Machado, J. C., Ianiro, G., Gasbarrini, A., Leja, M., Gisbert, J. P.,& Hold, G. L.. (2020). Systematic review: gastric microbiota in health and disease. in Alimentary Pharmacology & Therapeutics
Wiley, Hoboken., 51(6), 582-602.
https://doi.org/10.1111/apt.15650

Rajilić-Stojanović M, Figueiredo C, Smet A, Hansen R, Kupcinskas J, Rokkas T, Andersen L, Machado JC, Ianiro G, Gasbarrini A, Leja M, Gisbert JP, Hold GL. Systematic review: gastric microbiota in health and disease. in Alimentary Pharmacology & Therapeutics. 2020;51(6):582-602.
doi:10.1111/apt.15650 .

Rajilić-Stojanović, Mirjana, Figueiredo, Ceu, Smet, Annemieke, Hansen, Richard, Kupcinskas, Juozas, Rokkas, Theo, Andersen, Leif, Machado, Jose C., Ianiro, Gianluca, Gasbarrini, Antonio, Leja, Marcis, Gisbert, Javier P., Hold, Georgina L., "Systematic review: gastric microbiota in health and disease" in Alimentary Pharmacology & Therapeutics, 51, no. 6 (2020):582-602,
https://doi.org/10.1111/apt.15650 . .